Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal trial
PLSE•Pulse Biosciences enrolled 164 evaluable patients at 15 U.S. sites in its pivotal NANOPULSE-AF study of the nPulse catheter system for atrial fibrillation; patient follow-up is now underway.
1. Enrollment target reached
Pulse Biosciences reached its enrollment target in the NANOPULSE-AF IDE pivotal study of its nPulse cardiac catheter system for atrial fibrillation. The trial enrolled 164 evaluable patients across 15 U.S. clinical sites, and the program has moved into patient follow-up and study completion.
2. Results not yet reported
The announcement did not present clinical results. Management highlighted enrollment ahead of plan and said the progress supports timelines for potential regulatory and commercialization milestones.
